CRABP-II Inhibitors

CRABP-II Inhibitors encompass a range of compounds that indirectly influence the activity of Cellular retinoic acid-binding protein 2, primarily by modulating the metabolic pathways of retinoic acid or altering its signaling processes. These inhibitors do not directly target CRABP-II but affect the availability, synthesis, or action of retinoic acid, thereby influencing CRABP-II's functional role in cells. Compounds like Citral and Disulfiram, by inhibiting enzymes involved in retinoic acid synthesis, may lead to altered retinoic acid levels, potentially reducing the activity or requirement of CRABP-II in the cell.

The use of antifungal agents like Ketoconazole, Itraconazole, Voriconazole, and Fluconazole, known for their inhibitory effects on cytochrome P450 enzymes, presents another mechanism by which CRABP-II activity can be indirectly influenced. These drugs may impact the synthesis and metabolism of retinoic acid, thereby modulating CRABP-II function. Interestingly, certain retinoids such as Isotretinoin and Bexarotene, despite being related to retinoic acid, can disrupt normal retinoic acid metabolism or signaling under specific conditions, thereby affecting CRABP-II activity. Similarly, Tetracycline and Minocycline, through their interactions with cytochrome P450 enzymes, can influence retinoic acid metabolism. In some scenarios, the use of ATRA CYP26 Inhibitors, typically increasing retinoic acid levels, can paradoxically disrupt normal retinoic acid metabolism, potentially reducing CRABP-II's functional role. Alitretinoin, another retinoid, can alter retinoid signaling pathways and, in specific contexts, might reduce the requirement for CRABP-II.